Measurement of factor VIII activity of efraloctocog alfa with commercially available one-stage clotting and chromogenic assays: Results from the Belgian national External Quality Assessment Scheme
Sir, Modified factor VIII (FVIII) and factor IX products with extended half-lives (EHL) are currently being introduced into routine clinical practice. The modification applied to these molecules has introduced variations in their activity measurement, and some marked differences between the results of different assays have been described for some EHL FVIII and EHL FIX. [1] [2] [3] [4] However, accurate measurement of these clotting factors is essential to avoid under-or overtreatment of patients and an unnecessary search for inhibitor antibodies. 1 | ME THODS
.| Sample material and distribution
For this purpose, the Belgian national External Quality Assessment Scheme (EQAS) for blood coagulation organized in December 2016 a survey which included a sample from a patient with severe haemophilia A collected 1 hour after infusion of 4000 U of rFVIIIFc and obtained following informed consent. The sample was collected into 0.106 mol/L citrate. After centrifugation and separation, the plasma was buffered with HEPES and lyophilized prior to distribution through the post at room temperature. The sample was tested negative for hepatitis B surface antigen and antibodies to hepatitis C virus and human immunodeficiency viruses 1 and 2.
. 2 | Sample analysis
Participants were requested to reconstitute the lyophilized plasma with 1.0 mL distilled water and to incubate it with gentle mixing for at least 15 minutes at room temperature before analysis. They were asked to determine FVIII:C according to their usual procedures and to record the reagents and analyser used for testing.
. 3 | Statistical analysis
Method-specific medians and robust standard deviations were calculated for all methods with ≥6 reported results (interquartile range-based method of Tukey). Differences between methods were assessed by means of non-parametric statistics (Wilcoxon signed rank test with subsequent Bonferroni correction of the P-values). Pvalues < 0.05 were considered to be statistically significant. Table 1 . Except for three laboratories, all participants used aPTT reagent, calibration plasma, factor-deficient plasma and instrument from the same manufacturer.
| RE SULTS
The four chromogenic assays were as follows: Biophen FVIII:C | e21
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The results obtained by the one-stage clotting assays and chromogenic methods are summarized in Table 2 . The overall median and STA-Unicalibrator (Diagnostica Stago), respectively. There was only a significant difference between the results obtained with the Stago and Siemens calibration plasma (P = 0.0017). Table 3 shows the chromogenic FVIII assay results in relation to the calibrator used.
For the Biophen FVIII:C reagent, results tended to be slightly higher when the Biophen Plasma Calibrator (Hyphen BioMed) was used for assay calibration. Overall, a good agreement between the results was seen and none of the results deviated by more than 30% of the overall median value, which is the maximum bias that has been considered as acceptable.
| DISCUSS ION

4
In 2014, the authors of a comparative field study on rFVIIIFc Given the fact that all assays used in this study were calibrated with a plasma calibrator, our results confirm that a product-specific standard is not required for measuring FVIII:C in samples containing rFVIIIFc. 
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